The aim of the preclinical models platform is to:

• Characterize all models at a histological and molecular level (CGH and transcriptome typing, major mutations and miRNA)
• Collect clinical data,
• Conduct sensitivity testing on classic anti-cancer molecules so as to classify tumors according to their molecular type and / or sensitivity to conventional anti-tumor treatments and consequently form consistent groups,
• Isolate tumors presenting strong metastasing capabilities. The animals are dissected at each passage to detect metastases. To date, several tumors (breast, ovary) have been associated with spontaneous metastases.